Sanofi Q2 FY26 business EPS rises 33.3% to €2.09; net sales climb 17.8% to €11.6 billion - SNY News | RalliesSanofi Q2 FY26 business EPS rises 33.3% to €2.09; net sales climb 17.8% to €11.6 billion
S
SNY• Quarterly results
- Sanofi Q2 net sales rose 16% to €11.6 billion, while IFRS net income fell 91.3% to €343 million.
- IFRS EPS dropped 91% to €0.29; business EPS climbed 31.4% to €2.09.
- Dupixent sales increased 37.6% to €5.2 billion; vaccines sales declined 4.7% to €1.1 billion on a tough flu comparison.
- Pharma launches sales jumped 48.3% to €1.3 billion; R&D expenses rose 17.9% to €2.2 billion.
Guidance and outlook
- 2026 guidance was raised, with net sales now seen growing around 10% and business EPS expected to grow slightly faster.
